- Conditions
- CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
- Interventions
- Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2023
- U.S. locations
- 3
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 296
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Neoplasm
- Interventions
- MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Rhinitis, Allergic, Perennial and/or Seasonal
- Interventions
- Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 8
- States / cities
- Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
- Conditions
- Mucopolysaccharidosis II
- Interventions
- JR-141, Idursulfase, JR-141 or Idursulfase
- Drug
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Oakland, California • Chicago, Illinois + 4 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
- Conditions
- B-Cell Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Chronic Unexplained Nausea and Vomiting, Gastroparesis
- Interventions
- nVNS (gammaCore)
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Danirixin, Danirixin matching placebo, Standard of care, Rescue medication
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Topeka, Kansas • St Louis, Missouri + 5 more
- Conditions
- Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
- Interventions
- Adalimumab, Placebo
- Biological · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more
- Conditions
- Asthma
- Interventions
- FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
- Conditions
- Odontalgia, Toothache
- Interventions
- Epidiolex 100 mg/mL Oral Solution, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lung Neoplasm
- Interventions
- R-DXD, I-DXD, Docetaxel, Rescue Medications, Rescue Medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Dallas, Texas + 1 more
- Conditions
- Asthma
- Interventions
- Propeller Health device + asthma navigator
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Status Epilepticus
- Interventions
- Verbal Instructions Educational Intervention, Video Educational Intervention, Mannequin Educational Intervention
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Graft vs Host Disease
- Interventions
- high dose chemo and auto hematopoietic cell transplant
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Asthma
- Interventions
- Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 75
- States / cities
- Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
- Conditions
- Pelvic Pain
- Interventions
- Acetaminophen 1000mg PO, IV Acetaminophen 1000mg, IV Placebo, PO Placebo
- Drug · Other
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
- Conditions
- Pain, Postoperative
- Interventions
- continuous erector spinae block (ESB), continuous paravertebral block (PVB), Ropivacaine
- Procedure · Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 1 Month to 12 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
- Interventions
- Propeller Health intervention
- Device
- Lead sponsor
- David Van Sickle
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 17
- States / cities
- Oakland, California • Roseville, California • San Francisco, California + 13 more
- Conditions
- Opiate Antagonist Overdose, Opioid-Related Disorders
- Interventions
- Naloxone Auto-Injector
- Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Atopic Keratoconjunctivitis
- Interventions
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Drug
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more